尽管已采用传统内镜疗法治疗食道及胃静脉曲张（EV、GV），肝细胞癌（HCC）合并静脉曲张出血患者的再出血率仍然偏高。据报道，静脉曲张再出血的次级预防可改善HCC患者的预后，但最佳内镜治疗方式尚未明确。在此难以处理的人群中，传统内镜治疗后静脉曲张再出血率仍然相当高。
适应症：Hepatocellular Carcinoma、Variceal Bleeding
入组条件
纳入标准
- Consecutive HCC patients age 18 or older with recent (within 4 weeks of the episode) EV or GV bleeding successfully controlled by conventional endoscopic therapies (VBL for EV or glue injection for GV)
- Able to provide written informed consent to participate in the study and comply with the study procedures
排除标准
- Unable to provide written informed consent
- Contraindications for endoscopy due to underlying comorbidities
- HCC patients with non-variceal source of gastrointestinal bleeding
- Refractory coagulopathy (INR\>1.5) or refractory thrombocytopenia (platelets \<50,000) despite blood product transfusion
- Moribund patients from terminal illness
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。